image
Integra LifeSciences Holdings Corporation IART
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 13.56
1.45 %
$ 1.05 B
Market Cap
-34.97
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IART stock under the worst case scenario is HIDDEN Compared to the current market price of 13.6 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IART stock under the base case scenario is HIDDEN Compared to the current market price of 13.6 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one IART stock under the best case scenario is HIDDEN Compared to the current market price of 13.6 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart IART

image
1M 0%
6M -77%
1Y -113.0%
3Y -301%
5Y -254%
All
$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.61 B REVENUE
4.47%
Growth Rates
1Year 4.47%
3Years 1.45%
5Years 1.20%
7Years 4.44%
10Years 5.66%
28.4 M OPERATING INCOME
-74.53%
Growth Rates
1Year -74.53%
3Years -47.58%
5Years -30.79%
7Years -6.30%
10Years -8.02%
-6.94 M NET INCOME
-10.25%
Growth Rates
1Year -10.25%
3Years -1.35%
5Years -2.63%
7Years -1.47%
10Years -1.88%
129 M OPERATING CASH FLOW
-7.55%
Growth Rates
1Year -7.55%
3Years -25.46%
5Years -19.11%
7Years 1.76%
10Years 5.00%
-391 M INVESTING CASH FLOW
-314.97%
Growth Rates
1Year -314.97%
3Years -34.27%
5Years -5.10%
7Years 15.02%
10Years -0.73%
238 M FINANCING CASH FLOW
203.45%
Growth Rates
1Year 203.45%
3Years 64.13%
5Years 29.84%
7Years -20.34%
10Years -0.20%
383 M REVENUE
-13.55%
Growth Rates
1Year 4.47%
3Years 1.45%
5Years 1.20%
7Years 4.44%
10Years 5.66%
-15.5 M OPERATING INCOME
-43.50%
Growth Rates
1Year -74.53%
3Years -47.58%
5Years -30.79%
7Years -6.30%
10Years -8.02%
-25.3 M NET INCOME
0.00%
Growth Rates
1Year -10.25%
3Years -1.35%
5Years -2.63%
7Years -1.47%
10Years -1.88%
-11.3 M OPERATING CASH FLOW
-22.19%
Growth Rates
1Year -7.55%
3Years -25.46%
5Years -19.11%
7Years 1.76%
10Years 5.00%
-35.9 M INVESTING CASH FLOW
-745.38%
Growth Rates
1Year -314.97%
3Years -34.27%
5Years -5.10%
7Years 15.02%
10Years -0.73%
35.4 M FINANCING CASH FLOW
594.78%
Growth Rates
1Year 203.45%
3Years 64.13%
5Years 29.84%
7Years -20.34%
10Years -0.20%
Balance Sheet Integra LifeSciences Holdings Corporation
image
Current Assets 1.08 B
Cash & Short-Term Investments 274 M
Receivables 272 M
Other Current Assets 536 M
Non-Current Assets 2.96 B
Long-Term Investments 0
PP&E 550 M
Other Non-Current Assets 2.41 B
6.78 %6.75 %13.27 %13.62 %59.59 %Total Assets$4.0b
Current Liabilities 922 M
Accounts Payable 82.5 M
Short-Term Debt 607 M
Other Current Liabilities 233 M
Non-Current Liabilities 1.57 B
Long-Term Debt 1.2 B
Other Non-Current Liabilities 374 M
3.31 %24.36 %9.33 %47.99 %15.01 %Total Liabilities$2.5b
EFFICIENCY
Earnings Waterfall Integra LifeSciences Holdings Corporation
image
Revenue 1.61 B
Cost Of Revenue 728 M
Gross Profit 882 M
Operating Expenses 854 M
Operating Income 28.4 M
Other Expenses 35.4 M
Net Income -6.94 M
2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m00(200m)(200m)2b(728m)882m(854m)28m(35m)(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.77% GROSS MARGIN
54.77%
Averages
1Year 54.77%
3Years 58.23%
5Years 59.59%
7Years 60.28%
10Years 61.31%
1.76% OPERATING MARGIN
1.76%
Averages
1Year 1.76%
3Years 8.11%
5Years 9.63%
7Years 9.64%
10Years 9.19%
-0.43% NET MARGIN
-0.43%
Averages
1Year -0.43%
3Years 5.18%
5Years 7.26%
7Years 6.24%
10Years 5.63%
-0.45% ROE
-0.45%
Averages
1Year -0.45%
3Years 4.61%
5Years 6.54%
7Years 5.81%
10Years 5.58%
-0.17% ROA
-0.17%
Averages
1Year -0.17%
3Years 2.09%
5Years 2.89%
7Years 2.56%
10Years 2.39%
0.29% ROIC
0.29%
Averages
1Year 0.29%
3Years 2.83%
5Years 3.87%
7Years 4.05%
10Years 4.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Integra LifeSciences Holdings Corporation
image
300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -6.94 M
Depreciation & Amortization 141 M
Capital Expenditures -104 M
Stock-Based Compensation 24.4 M
Change in Working Capital 0
Others -8.21 M
Free Cash Flow 25 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Integra LifeSciences Holdings Corporation
image
Wall Street analysts predict an average 1-year price target for IART of $24.6 , with forecasts ranging from a low of $20 to a high of $32 .
IART Lowest Price Target Wall Street Target
20 USD 47.49%
IART Average Price Target Wall Street Target
24.6 USD 81.42%
IART Highest Price Target Wall Street Target
32 USD 135.99%
Price
Max Price Target
Min Price Target
Average Price Target
32323030282826262424222220201818161614141212Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Integra LifeSciences Holdings Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
141 K USD 2
9-12 MONTHS
25.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue? Integra (IART) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK , June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
Is the Options Market Predicting a Spike in Integra LifeSciences Stock? Investors need to pay close attention to Integra LifeSciences stock based on the movements in the options market lately. zacks.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Integra LifeSciences Holdings Corporation (IART) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra" or "the Company") (NASDAQ:IART). Investors who purchased Integra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IART. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
Integra LifeSciences Holdings Corporation (IART) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra" or "the Company") (NASDAQ:IART). Investors who purchased Integra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IART. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
8. Profile Summary

Integra LifeSciences Holdings Corporation IART

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.05 B
Dividend Yield 0.00%
Description Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Contact 1100 Campus Road, Princeton, NJ, 08540 https://www.integralife.com
IPO Date Aug. 16, 1995
Employees 4396
Officers Ms. Mojdeh Poul President, Chief Executive Officer & Director Christopher Ward Senior Director of Investor Relations Laurene Isip Vice President of Global Corporate Communications & Public Relations Mr. Robert T. Davis Jr. Executive Vice President & President of Tissue Technologies Mr. Jeffrey A. Mosebrook Senior Vice President of Finance & Principal Accounting Officer Mr. Michael J. McBreen Executive Vice President & President of Codman Specialty Surgical Dr. Stuart M. Essig Ph.D. Non- Executive Chairman Ms. Lea Daniels Knight Executive Vice President & Chief Financial Officer Mr. Harvinder Singh Executive Vice President & President of International Business Mr. Stephen Leonard Corporate Vice President of Global Operations & Supply Chain